Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bianco, L. Li, F. Molica, J. C. Pache, G. Laurent, N. De Rosa, I. Irminger-Finger (Campobasso, Italy; Geneva, Switzerland; London, United Kingdom). Distinct BARD1 isoforms expressed in lung cancer potential targets for treatment. Eur Respir J 2008; 32: Suppl. 52, 3006

Member's Comments

No comment yet.

Related content which might interest you: Truncated isoforms of BRCA1-associated protein BARD1 are expressed in NSCLC and are potential targets for treatment Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Oral presentation: Truncated isoforms of BRCA1-associated protein BARD1 are expressed in NSCLC and are potential targets for treatment Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Distinct forms of BARD1 expressed in lung fibrosis and lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 325s Year: 2006 Cancer-associated oncogenic BARD1 isoforms: From biomarker expression studies to development of a blood test for early detection of lung cancer Source: Annual Congress 2012 - Early detection of lung cancer Year: 2012 Differential expression analysis of lncRNA in different types of lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 Overexpression of inhibitor of DNA-binding proteins and angiogenic markers have higher impact on survival of non small cell lung cancer patients Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer Source: Annual Congress 2003 - Lung cancer biology Year: 2003 Identification of the mobile elements differentially expressed in lung cancer Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Gene expression profiling reveal novel biomarkers in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient Source: Eur Respir J , 49 (4)  1602149; DOI: 10.1183/13993003.02149-2016 Year: 2017 Over-expression of aquaporin-5 increases migration and metastatic potential of lung cancer cells Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009 Mouse lung adenocarcinoma cell lines as tools to identify novel lung cancer genes Source: ERS Lung Science Conference 2017 Year: 2017 Activation of NRF2 is responsible for the overexpression of peroxiredoxin and sulphiredoxin in human lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Fusion transcripts in lung cancer Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006